0001104659-16-123339.txt : 20160525 0001104659-16-123339.hdr.sgml : 20160525 20160525161657 ACCESSION NUMBER: 0001104659-16-123339 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160525 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160525 DATE AS OF CHANGE: 20160525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STEMLINE THERAPEUTICS INC CENTRAL INDEX KEY: 0001264587 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450522567 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35619 FILM NUMBER: 161674854 BUSINESS ADDRESS: STREET 1: 750 LEXINGTON AVENUE STREET 2: ELEVENTH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 646-502-2311 MAIL ADDRESS: STREET 1: 750 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 a16-12230_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  May 25, 2016

 

Stemline Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State or Other Jurisdiction
of Incorporation)

 

001-35619
(Commission File Number)

 

45-0522567
(IRS Employer Identification No.)

 

750 Lexington Avenue

Eleventh Floor

New York, New York 10022

(Address of Principal Executive Offices)

 

(646) 502-2311

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act.

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

o                                    Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

 


 

Item 5.07.                                        Submission of Matters to a Vote of Security Holders.

 

The 2016 annual meeting of stockholders of Stemline Therapeutics, Inc. (“Stemline”) was held on May 25, 2016.  The following matters were voted on by the stockholders: the election of one director, the ratification of the appointment of Ernst & Young LLP as Stemline’s independent registered public accounting firm for the year ending December 31, 2016, and the approval of Stemline’s 2016 Equity Incentive Plan.

 

The vote with respect to the nominees for director is set forth below:

 

Nominee

 

Total Votes For

 

Total Votes
Withheld

 

Broker Non-Votes

 

Kenneth Zuerblis

 

11,258,681

 

29,418

 

3,420,009

 

 

The vote with respect to the ratification of the appointment of Ernst & Young LLP as Stemline’s independent registered public accounting firm for the year ending December 31, 2016 is set forth below:

 

Total Votes For

 

Total Votes Against

 

Abstention

 

Broker Non-Votes

 

14,595,593

 

110,510

 

2,005

 

0

 

 

The vote with respect to the approval of Stemline’s 2016 Equity Incentive Plan is set forth below:

 

Total Votes For

 

Total Votes Against

 

Abstention

 

Broker Non-Votes

 

10,838,144

 

430,180

 

19,775

 

3,420,009

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Stemline Therapeutics, Inc.

 

(Registrant)

 

 

 

 

Date: May 25, 2016

 

 

 

 

By:

/s/ Kenneth Hoberman

 

 

Kenneth Hoberman

 

 

Chief Operating Officer

 

3